Hepatology
From the Journals
New antiviral combination for HCV infection in kidney disease
Glecaprevir and pibrentasvir exhibit potent antiviral activity across all six major HCV genotypes.
From the Journals
Study supports routine rapid HCV testing for at-risk youth
Routine finger-stick testing was the most cost-effective way to screen urban adolescents and young adults for hepatitis C virus infection.
News from the FDA/CDC
To boost HCV testing in baby boomers, offer the option
Offer the test, and they’ll probably take it.
Feature
Hepatitis C drug’s lower cost paves way for Medicaid, prisons to expand treatment
The recent approval of a less expensive drug that generally cures hepatitis C in just eight weeks may make it easier for more insurers and...
Case Reports
Fever, rash, and leukopenia in a 32-year-old man • Dx?
► Fever
► Rash
► Leukopenia
From the Journals
VIDEO: Alcohol showed no cardiovascular benefits in nonalcoholic fatty liver disease
Long-term prospective studies are needed to better understand how types and doses of alcohol affect cardiovascular endpoints in patients with...
From the Journals
VA shares its best practices to achieve HCV ‘cascade of cure’
The VA “cascade of cure” for HCV has achieved sharp reductions in infection rates among veterans.
From the Journals
Sharing drug paraphernalia alone didn’t transmit HCV
Should shared drug preparation paraphernalia be a primary focus of harm-reduction and education?
Conference Coverage
Hepatitis C falls as barrier to heart transplantation
GRAPEVINE, TEXAS – Transplant recipients, whether naive or previously exposed to HCV, eradicated the virus with direct-acting antiviral therapy....
From the Journals
Statin use cuts risks in compensated cirrhosis
Hepatic decompensation and mortality dropped 46% in patients with compensated cirrhosis of any etiology.
News from the FDA/CDC
FDA approves faster, pangenotypic cure for hep C virus
A faster cure for all genotypes of the hepatitis C virus with or without liver disease comes to market.